D.E. Shaw & Co’s Eli Lilly LLY Stock Holding History

D.E. Shaw & Co’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$171M	Sell	185,700 -80,600	-30%	-$81.7M	0.1%	228
2025 Q4	$286M	Sell	266,300 -46,500	-15%	-$44.5M	0.16%	122
2025 Q3	$239M	Buy	312,800 +97,300	+45%	+$72.4M	0.13%	161
2025 Q2	$168M	Buy	215,500 +46,600	+28%	+$36.2M	0.12%	197
2025 Q1	$139M	Sell	168,900 -209,300	-55%	-$174M	0.12%	194
2024 Q4	$292M	Sell	378,200 -33,500	-8%	-$27.7M	0.21%	88
2024 Q3	$365M	Buy	411,700 +79,700	+24%	+$71.7M	0.31%	48
2024 Q2	$301M	Sell	332,000 -53,200	-14%	-$42.6M	0.28%	58
2024 Q1	$300M	Buy	385,200 +35,900	+10%	+$25.5M	0.26%	75
2023 Q4	$204M	Buy	349,300 +81,400	+30%	+$47.5M	0.18%	120
2023 Q3	$144M	Buy	267,900 +74,100	+38%	+$38.2M	0.15%	149
2023 Q2	$90.9M	Buy	193,800 +123,600	+176%	+$51.8M	0.09%	253
2023 Q1	$24.1M	Sell	70,200 -20,000	-22%	-$6.75M	0.03%	778
2022 Q4	$33M	Buy	90,200 +28,500	+46%	+$10.1M	0.04%	623
2022 Q3	$20M	Sell	61,700 -72,800	-54%	-$23.1M	0.02%	846
2022 Q2	$43.6M	Buy	134,500 +24,500	+22%	+$7.35M	0.05%	459
2022 Q1	$31.5M	Buy	110,000 +10,000	+10%	+$2.57M	0.03%	725
2021 Q4	$27.6M	Buy	100,000 +40,000	+67%	+$10.1M	0.02%	873
2021 Q3	$13.9M	Buy	60,000 +20,000	+50%	+$4.94M	0.01%	1268
2021 Q2	$9.18M	Buy	40,000 +30,000	+300%	+$6.03M	0.01%	1567
2021 Q1	$1.87M	Sell	10,000 -26,000	-72%	-$5.09M	﹤0.01%	2649
2020 Q4	$6.08M	Sell	36,000 -24,500	-40%	-$3.66M	0.01%	1722
2020 Q3	$8.96M	Sell	60,500 -48,300	-44%	-$7.48M	0.01%	1312
2020 Q2	$17.9M	Sell	108,800 -14,100	-11%	-$2.16M	0.02%	842
2020 Q1	$17M	Sell	122,900 -25,100	-17%	-$3.45M	0.03%	714
2019 Q4	$19.5M	Sell	148,000 -25,000	-14%	-$2.9M	0.02%	835
2019 Q3	$19.3M	Hold	173,000	–	–	0.02%	789
2019 Q2	$19.2M	Sell	173,000 -487,700	-74%	-$57.4M	0.02%	774
2019 Q1	$85.7M	Buy	660,700 +506,700	+329%	+$61.6M	0.11%	217
2018 Q4	$17.8M	Buy	154,000 +90,100	+141%	+$10.1M	0.02%	761
2018 Q3	$6.86M	Buy	63,900 +54,600	+587%	+$5.46M	0.01%	1355
2018 Q2	$794K	Buy	+9,300	New	+$764K	﹤0.01%	2837
2017 Q2	–	Sell	-13,300	Closed	-$1.12M	–	3466
2017 Q1	$1.12M	Buy	+13,300	New	+$1.07M	﹤0.01%	2230
2016 Q4	–	Sell	-175,100	Closed	-$14.1M	–	3527
2016 Q3	$14.1M	Buy	+175,100	New	+$14M	0.02%	721
2016 Q2	–	Sell	-118,400	Closed	-$8.53M	–	3441
2016 Q1	$8.53M	Sell	118,400 -50,000	-30%	-$3.78M	0.02%	948
2015 Q4	$14.2M	Buy	168,400 +71,800	+74%	+$5.96M	0.02%	792
2015 Q3	$8.08M	Hold	96,600	–	–	0.01%	1089
2015 Q2	$8.06M	Buy	96,600 +86,600	+866%	+$6.6M	0.01%	1148
2015 Q1	$727K	Sell	10,000 -71,400	-88%	-$5.08M	﹤0.01%	2797
2014 Q4	$5.62M	Sell	81,400 -69,400	-46%	-$4.68M	0.01%	1476
2014 Q3	$9.78M	Buy	150,800 +121,100	+408%	+$7.67M	0.01%	1098
2014 Q2	$1.85M	Buy	29,700 +9,700	+49%	+$579K	﹤0.01%	2374
2014 Q1	$1.18M	Sell	20,000 -483,300	-96%	-$27M	﹤0.01%	2877
2013 Q4	$25.7M	Hold	503,300	–	–	0.04%	551
2013 Q3	$25.3M	Sell	503,300 -134,600	-21%	-$7.05M	0.04%	481
2013 Q2	$31.3M	Buy	+637,900	New	+$34.7M	0.06%	359

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co's LLY Position: Q1 2026 in Review

D.E. Shaw & Co increased its Eli Lilly (LLY) stake by 52% in Q1 2026, buying an estimated $221M and bringing the position to 637,382 shares worth $586M. The position accounts for 0.35% of the portfolio, ranked #39.

D.E. Shaw & Co first reported a position in LLY in Q2 2013 and has held it in 51 quarters since. The position peaked at $958M in Q4 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

D.E. Shaw & Co held 637,382 shares of Eli Lilly worth $586M as of Q1 2026.
D.E. Shaw & Co bought 218,331 Eli Lilly shares in Q1 2026, an estimated $221M.
Eli Lilly made up 0.35% of D.E. Shaw & Co's portfolio in Q1 2026, its #39 holding.
D.E. Shaw & Co first reported a position in Eli Lilly in Q2 2013 and has held it in 51 quarters since.
D.E. Shaw & Co's Eli Lilly position peaked at $958M in Q4 2024.
4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.